1.Efficacy of Blinatumomab in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia.
Jian WANG ; Ya-Ting ZHANG ; Kai-Mei WANG ; Jian-Pei FANG ; Dun-Hua ZHOU
Journal of Experimental Hematology 2025;33(3):698-705
OBJECTIVE:
To retrospectively analyze the clinical characteristics of 15 children with B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab, and summarize the efficacy and safety of blinatumomab in the treatment of pediatric B-ALL.
METHODS:
Fifteen children who received treatment with blinatumomab from February 2022 to January 2023 were enrolled in this study. One course (28 days) of blinatumomab concurrent with intrathecal chemotherapy was given according to the standard regimen, except for 2 cases who had shortened course of treatment due to hematopoietic stem cell transplantation (HSCT) and did not receive combined intrathecal chemotherapy, and 1 case had a shortened course of treatment due to economic problems. The efficacy and safety of the treatment were evaluated.
RESULTS:
In terms of efficacy, for the children who had achieved complete molecular remission (CMR) before treatment, blinatumomab treatment could effectively maintain CMR status; For the children who did not achieve CMR, the CMR rate after one standard course of treatment with blinatumomab reached 66.7%(4/6); For the children with relapsed/refractory ALL (R/R ALL) who had minimal residual disease (MRD), the MRD clearance rate reached 75.0%(3/4). The statistical results of the incidence of adverse events showed that 13.3%(2/15) of the children did not experience any adverse events. The most common adverse events were cytokine release syndrome (CRS) (73.3%, 11/15) and transaminase elevation (26.7%, 4/15); 33.3%(5/15) of the children experienced grade 3 or higher adverse events. All the adverse events were resolved after symptomatic treatment.The level of IgG decreased significantly after 4-7 weeks of treatment with blinatumomab, and gradually recovered after 8 weeks of treatment.
CONCLUSION
Blinatumomab can be used as a safe and effective treatment for inducing deep remission in pediatric R/R-ALL patients and as a bridge therapy for the pediatric ALL patients who are intolerant to chemotherapy.
Humans
;
Antibodies, Bispecific/therapeutic use*
;
Child
;
Retrospective Studies
;
Female
;
Male
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
;
Remission Induction
;
Treatment Outcome
;
Child, Preschool
;
Adolescent
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
2.Ferroptosis contributes to immunosuppression.
Nina HE ; Dun YUAN ; Minjie LUO ; Qing XU ; Zhongchi WEN ; Ziqin WANG ; Jie ZHAO ; Ying LIU
Frontiers of Medicine 2025;19(1):1-22
As a novel form of cell death, ferroptosis is mainly regulated by the accumulation of soluble iron ions in the cytoplasm and the production of lipid peroxides and is closely associated with several diseases, including acute kidney injury, ischemic reperfusion injury, neurodegenerative diseases, and cancer. The term "immunosuppression" refers to various factors that can directly harm immune cells' structure and function and affect the synthesis, release, and biological activity of immune molecules, leading to the insufficient response of the immune system to antigen production, failure to successfully resist the invasion of foreign pathogens, and even organ damage and metabolic disorders. An immunosuppressive phase commonly occurs in the progression of many ferroptosis-related diseases, and ferroptosis can directly inhibit immune cell function. However, the relationship between ferroptosis and immunosuppression has not yet been published due to their complicated interactions in various diseases. Therefore, this review deeply discusses the contribution of ferroptosis to immunosuppression in specific cases. In addition to offering new therapeutic targets for ferroptosis-related diseases, the findings will help clarify the issues on how ferroptosis contributes to immunosuppression.
Ferroptosis/immunology*
;
Humans
;
Immune Tolerance/immunology*
;
Animals
;
Immunosuppression Therapy
;
Iron/metabolism*
;
Neoplasms/immunology*
3.Study on the Role of Nrf2/SLC7A11/GPX4 Signaling Pathway in the Pathogenesis of Ischemic Stroke and Research Progress on Traditional Chinese Medicine Intervention Based on Ferroptosis
Dacheng WEI ; Linglu DUN ; Changjun LU ; Hongwei AN ; Man WANG ; Qichao YE ; Hanchi LIANG
Journal of Guangzhou University of Traditional Chinese Medicine 2025;42(7):1825-1830
Ischemic stroke is a disease resulting from the cerebral ischemia and hypoxia caused by the blockage of brain vessels in the brain,and is characterized by the focal neurological signs.Pathologically,neuronal necrosis in the infarcted area and the neuronal degeneration or delayed death of neurons in the ischemic penumbra,contribute to the morphological basis of the disease.Ischemic stroke is regulated by multiple processes,including ferroptosis,apoptosis,and autophagy.Ferroptosis,a type of iron-dependent cell death,is closely associated with ischemic stroke.Nuclear factor erythroid 2-related factor 2(Nrf2),a key transcription factor,plays a critical role in maintaining cellular redox balance and regulating inflammatory responses.Nrf2 promotes the expression of solute carrier family 7 member 11(SLC7A11)and glutathione peroxidase 4(GPX4),thereby activating the Nrf2 signaling pathway to counteract ferroptosis and protect cells from damage.This article reviews and analyzes recent experimental studies on traditional Chinese medicine(TCM)therapy targeting the Nrf2/SLC7A11/GPX4 pathway to suppress ferroptosis.The studies have found that TCM therapy with herbal compounds,Chinese patent medicines,single herbal components and their active ingredients,and acupuncture and moxibustion can inhibit ferroptosis by activating the Nrf2/SLC7A11/GPX4 signaling pathway,which will provide novel strategies for the TCM intervention of ischemic stroke.
4.Clinical Efficacy of Acupuncture Combined With Acupoint Patching in Treating Chronic Pelvic Pain as a Sequela of Pelvic Inflammatory Disease
Juyan DUN ; Fen WANG ; Liying TIAN
Journal of Sichuan University (Medical Sciences) 2025;56(3):672-677
Objective To investigate the efficacy of acupuncture therapy combined with acupoint patching in alleviating chronic pelvic pain,a sequela of pelvic inflammatory disease(SPID-CPP).Methods A total of 120 SPID-CPP patients attending our hospital between January 2022 and November 2024 were enrolled and randomly assigned to either an experimental group or a control group,with 60 patients in each group.Both groups received conventional lifestyle guidance and anti-infection therapy.The control group received only acupuncture therapy,while the observation group received acupuncture combined with acupoint patching therapy.The duration of treatment was identical for both groups.The treatment effect,levels of high-sensitivity C-reactive protein(hs-CRP),white blood cell count(WBC),neutrophil percentage(NEUT),fibrinogen(FIB)level,quality-of-life scores,and visual analog scale(VAS)pain scores were compared between the experimental and control groups.Results The treatment efficacy rate of the experimental group was 93.00%,while that of the control group was only 73.33%,and the difference between the two groups was statistically significant(P<0.05).Following therapy,the hs-CRP,WBC,NEUT,and VAS ratings of both the control and experimental groups decreased.Furthermore,findings of the experimental group were significantly lower than those of the control group(P<0.05).The quality-of-life score of the experimental group was higher than that of the control group(P<0.05).Conclusion Acupuncture combined with acupoint patching demonstrates significant efficacy in treating SPID-CPP.This combined therapy effectively reduces pain in SPID-CPP patients,decreases serum levels of inflammatory factors,and significantly improves patients'quality of life.
5.Advances in acute Stanford type A aortic dissection with organ malperfusion
Bowen ZHANG ; Yaojun DUN ; Yanxiang LIU ; Haoyu GAO ; Jie REN ; Luchen WANG ; Sangyu ZHOU ; Mingxin XIE ; Xiaogang SUN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2024;31(08):1235-1241
The treatment of acute Stanford type A aortic dissection has always been extremely challenging. Organ malperfusion syndrome is a common severe complication of acute aortic dissection, which can cause organ ischemia and internal environment disorder. Malperfusion increases early mortality, and impacts the long-term prognosis. In recent years, many scholars have done some studies on aortic dissection complicated with malperfusion. They explored the pathogenesis, proposed new classification, and innovated new treatment strategies. However, at present, the treatment strategies of acute Stanford type A aortic dissection complicated with organ malperfusion are different at different centers and consensus on its treatment is still lacking. Therefore, this review summarized the pathogenesis, classification, treatment strategy, and prognosis of acute Stanford type A aortic dissection complicated with malperfusion.
6.Application and effectiveness of SPD management of consumables and reagents in a public hospital
Jinyi WANG ; Haiqing XU ; Yuzhi YANG ; Wenru ZENG ; Dun LIU ; Siyu MA
Chinese Journal of Hospital Administration 2024;40(1):59-63
In the context of high-quality development in medical institutions, the supply-processing-distribution(SPD) management mode has gradually been widely applied. The authors described in detail the procurement, supply, inventory, distribution, and settlement management of medical consumables and in vitro diagnostic reagents in a certain hospital under the SPD mode. It was found that SPD was conducive to strengthening the supervision of medical consumables and in vitro diagnostic reagents in the hospital, ensuring quality and safety of use, reducing hospital operating costs, and improving hospital′s competitiveness. However, attention should be paid to preventing data security risks, strengthening operational management, and improving the cost-benefit analysis of in vitro diagnostic reagents.
7.Two Cases of Dyskeratosis Congenita in Pediatric Children and Literature Review
Jianxin DUN ; Qun HU ; Aiguo LIU ; Yaqin WANG
Herald of Medicine 2024;43(12):1977-1980
Objective To report two cases of dyskeratosis congenita(DC)and provide a comprehensive literature review to improve the understanding of the disease.Methods Clinical characteristics of two DC cases were retrospectively collected and analyzed in Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology.Gene mutations were assessed by high-throughput sequencing analysis and telomere length was assessed by Terminal Restriction Fragment(TRF)analysis.A literature search was carried out using the National Knowledge Infrastructure(CNKI),Wanfang database,PubMed,and Web of Science,updated to June 2024,with"Dyskeratosis congenita"and"telomere biology disorders"as the keywords.Results Case 1 was a boy admitted with"nail dystrophy of fingers and toes for more than 8 years and pancytopenia for 1 week".Physical examination revealed fingernails and toenails dysplasia,reticular skin pigmentation over the neck,and restricted mouth opening.Genetic testing identified a mutation in the DKC1 gene and shorter telomeres.Case 2 was a girl admitted with"confirmed aplastic anemia over 3 years".Physical examination showed no specific abnormalities.A blood routine test showed pancytopenia,with missense mutations found in the RTEL1 and TERT genes.Case 1 received blood transfusion support,while Case 2 was treated with subcutaneous injections of PEGylated recombinant human granulocytes,cyclosporine,and eltrombopag olamine,but the outcomes were not satisfactory.Both cases developed bone marrow failure,prompting hematopoietic stem cell transplantation.However,both cases were lost to follow-up after discharge.Conclusions Dyskeratosis congenita is a rare disease with various clinical manifestations.It may present with skin manifestations or hematological abnormalities.A precise diagnosis is made through a genetic testing.Currently,efficacious medical treatment for DC is lacking,and hematopoietic stem cell transplantation is necessary for patients with bone marrow failure.
8.Clinical characteristics and prognostic analysis of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia
Dun JIANXIN ; Zhang AI ; Wang YAQIN ; Wang YAO ; Liu AIGUO ; Hu QUN
Chinese Journal of Clinical Oncology 2024;51(11):547-551
Objective:To analyze the clinical characteristics and risk factors of asparaginase-associated pancreatitis(AAP)in children with acute lymphoblastic leukemia(ALL),and to investigate the impact of AAP on their prognosis following re-exposure to asparaginase(ASP).Methods:Clinical children data with ALL at Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology between January 2015 and June 2020 were collected to analyze the clinical features of AAP.Logistic regression was used to identify risk factors for AAP.Prognostic analysis was performed using the Log-rank test and Kaplan-Meier survival curves.Results:Overall,252 children with ALL were included,among whom 23(9.1%)developed AAP.Most AAP cases(82.6%)occurred during remission induction,with a medi-an time from the last ASP to AAP of 12 d.Elevated total cholesterol(≥3.5 mmol/L)at initial diagnosis was identified as an independent risk factor.Six children(26.1%)were re-exposed to ASP,leading to recurrent pancreatitis in 3 cases.The 5-year overall survival(OS)was signific-antly lower in the AAP group(78.3%±8.6%)compared to the non-AAP group(90.3%±2.2%)(P<0.05).Similarly,children who discontinued ASP due to AAP had a 5-year OS of 77.8%±9.8%,significantly lower than the control group(90.1%±2.1%).Conclusions:AAP typically oc-curred within 12 d of the last ASP administration and was associated with poorer 5-year OS.Re-exposure to ASP posed a risk of recurrent AAP;however,completing the ASP chemotherapy regimen may be crucial for improving prognosis.
9.Successful treatment of 11 cases of livedoid vasculopathy with rivaroxaban alone or in combination with folic acid/methylprednisolone
Baichao CHEN ; Wenwen ZHANG ; Xuhui FU ; Geng DUN ; Qingna GENG ; Zhexin WANG
Chinese Journal of Dermatology 2024;57(10):939-943
Objective:To retrospectively analyze the clinical efficacy and safety of rivaroxaban alone or in combination with folic acid/methylprednisolone in the treatment of livedoid vasculopathy (LV) .Methods:Clinical data were retrospectively collected from LV patients who were treated with rivaroxaban alone or in combination at the Department of Dermatology, Kaifeng People's Hospital from April 2020 to September 2023. Before treatment, all the patients underwent serum folate and homocysteine tests. Folic acid therapy was given to patients with low folate levels; glucocorticoid therapy was given to patients with generalized skin lesions in the extremities in the acute stage or with dense inflammatory cell infiltration around the dermal vessels on histopathological examination. Clinical symptoms (erythema, ulceration and pain) were scored before and after 8 weeks of treatment. Adverse reactions were recorded during the treatment.Results:A total of 11 patients were collected, including 6 males and 5 females; their ages ranged from 15 to 73 (29.00 ± 17.85) years, and the disease duration ranged from 1 month to 4 years (13.36 ± 15.87 months). Among the 11 patients, 3 were treated with rivaroxaban combined with methylprednisolone and folate, 1 with rivaroxaban combined with methylprednisolone, 5 with rivaroxaban combined with folate, and 2 with rivaroxaban alone. The total score of clinical symptoms was 5.00 ± 2.28 points before treatment, and significantly decreased to 1.18 ± 0.75 points after 8 weeks of treatment with rivaroxaban alone or in combination ( t = 6.90, P = 0.001). In addition, the pain scores of 5 patients who reported pain dropped to 0 point after 8 weeks of treatment. One patient experienced coagulation abnormalities after 2 weeks of treatment, and the coagulation parameters returned to normal without special treatment after 4 weeks. Conclusion:Rivaroxaban alone or in combination with folic acid/methylprednisolone was effective for the treatment of LV with a good safety profile.
10.PRELIMINARY STUDY ON EGG RECOGNITION MODEL OF AEDES ALBOPICTUS BASED ON DEEP LEARNING
Min-Hui ZHU ; Lin-Juan DONG ; Dun-Jia WANG ; Yi-Zhou CAI ; Zhao-Wen ZHANG ; Yao LIU ; Shi-Peng HE ; Yi-Bin ZHOU
Acta Parasitologica et Medica Entomologica Sinica 2024;31(1):12-18
Objective In this study,a pictorial database of Aedes albopictus eggs was built to establish a model for the automatic recognition and counting of eggs of this mosquito species.Methods In total,449 images of Ae.albopictus eggs from field strains in three districts of Shanghai and laboratory strains were collected.The eggs were manually calibrated using the Python environment labeling library,and the faster region-based convolution neural network(Faster R-CNN)was used to train the model with the tile overlap method.Results The results of model validation evaluation using accuracy,recall,and F-measure showed that after 15 training sessions,the loss gradually decreased with increasing training frequency and ultimately decreased to 0.000119.The mean accuracy(mAP)increased from 0.968 to 0.980 with increasing training frequency.The final model had an accuracy of up to 0.90,a recall rate of 0.97,and an F-measure of 0.93.Conclusion The established model achieved its function of assisting in egg identification and counting.With further optimization of the model and refining of its classification and recognition capabilities,it will serve as a simple and efficient auxiliary monitoring tool.

Result Analysis
Print
Save
E-mail